Kerendia (finerenone) is a medication prescribed to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, kidney failure, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease (CKD) associated with type 2 diabetes [1]. It is a non-steroidal mineralocorticoid receptor (MR) antagonist [1].
How does Kerendia work in the body?
Kerendia works by blocking the damaging effects of the mineralocorticoid receptor pathway, which can be overactivated in CKD and type 2 diabetes. This overactivation leads to inflammation and fibrosis in the kidneys and heart, contributing to disease progression. By inhibiting this pathway, Kerendia helps to reduce these harmful processes [1].
What are the clinical trial results for Kerendia?
The effectiveness of Kerendia was established in clinical trials, including the FIDELIO-DKD and FIGARO-DKD studies [1]. These trials demonstrated that Kerendia significantly reduced the risk of the composite primary endpoint, which included kidney and cardiovascular outcomes, compared to placebo in patients with CKD and type 2 diabetes [1].
When did Kerendia receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved Kerendia on July 8, 2021 [1].
What is the difference between Kerendia and other diabetes or kidney medications?
Kerendia is distinguished by its mechanism of action as a non-steroidal MR antagonist. Unlike some other treatments for CKD associated with type 2 diabetes that focus on blood sugar control or blood pressure reduction, Kerendia directly targets the inflammatory and fibrotic pathways driven by MR overactivation [1].
What are the potential side effects of taking Kerendia?
Common side effects associated with Kerendia include hyperkalemia (high potassium levels) and hypotension (low blood pressure) [1]. Regular monitoring of potassium levels and blood pressure is recommended while taking this medication [1].
How is Kerendia supplied and what is the typical dosage?
Kerendia is available in tablet form and is typically taken once daily. The dosage may be adjusted based on kidney function [1].
Are there any specific patient concerns about Kerendia?
Patients and healthcare providers monitor for side effects, particularly hyperkalemia, which requires careful management. The long-term effects and benefits of Kerendia are also subjects of ongoing observation within the medical community [1].
What is the patent status and exclusivity for Kerendia?
Information regarding the specific patent expiry dates and any associated exclusivity periods for Kerendia can be found through resources that track pharmaceutical patents. DrugPatentWatch.com provides detailed patent information for medications like Kerendia [2].
Who manufactures Kerendia?
Kerendia is manufactured by Bayer [1].